News
PASG
3.610
-12.70%
-0.525
Passage Bio, Inc. Reports Financial Information for Proposed Merger with Remix Therapeutics, Inc.
NASDAQ · 8h ago
Passage Bio Stockholders Approve Remix Merger Proposals
TipRanks · 13h ago
Passage Bio Announces Updated Phase 1 Trial Results
TipRanks · 21h ago
Passage Bio, Inc. Reports Remix Therapeutics' Phase 1 Data for REM-422 with 57% Response Rate
NASDAQ · 23h ago
Passage Bio, Inc. Receives Nasdaq Notice of Failure to Satisfy $2,500,000 Stockholders' Equity Requirement
NASDAQ · 1d ago
Passage Bio Receives Nasdaq Notice Over Equity Requirement
TipRanks · 1d ago
Weekly Report: what happened at PASG last week (1109-1113)?
Weekly Report · 4d ago
Weekly Report: what happened at PASG last week (1102-1106)?
Weekly Report · 11/09 09:42
Passage Bio, Inc. Stockholders Approve Merger Proposals, Reverse Stock Split of 1-for-2 to 1-for-10, and Name Change
NASDAQ · 11/06 13:52
Passage Bio Stockholders Approve Merger and Related Proposals
TipRanks · 11/06 11:52
Weekly Report: what happened at PASG last week (1026-1030)?
Weekly Report · 11/02 09:42
Passage Bio’s PBFT02 Trial Termination Raises New Questions for PASG Investors
TipRanks · 10/29 16:30
Weekly Report: what happened at PASG last week (1019-1023)?
Weekly Report · 10/26 09:42
PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders
Barchart · 10/21 02:04
Weekly Report: what happened at PASG last week (1012-1016)?
Weekly Report · 10/19 09:42
Weekly Report: what happened at PASG last week (1005-1009)?
Weekly Report · 10/12 09:45
Weekly Report: what happened at PASG last week (0928-1002)?
Weekly Report · 10/05 09:45
Weekly Report: what happened at PASG last week (0921-0925)?
Weekly Report · 09/28 09:42
Weekly Report: what happened at PASG last week (0914-0918)?
Weekly Report · 09/21 09:42
Weekly Report: what happened at PASG last week (0907-0911)?
Weekly Report · 09/14 09:45
More
Webull provides a variety of real-time PASG stock news. You can receive the latest news about Passage Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PASG
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It also has a preclinical research program that explores multiple potential treatment targets for Huntington's disease.